JP2019517536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517536A5 JP2019517536A5 JP2018563716A JP2018563716A JP2019517536A5 JP 2019517536 A5 JP2019517536 A5 JP 2019517536A5 JP 2018563716 A JP2018563716 A JP 2018563716A JP 2018563716 A JP2018563716 A JP 2018563716A JP 2019517536 A5 JP2019517536 A5 JP 2019517536A5
- Authority
- JP
- Japan
- Prior art keywords
- flt3 receptor
- neuropathic
- pain
- daily dose
- receptor inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 37
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 37
- 108091006082 receptor inhibitors Proteins 0.000 claims 34
- 208000004296 neuralgia Diseases 0.000 claims 20
- 208000021722 neuropathic pain Diseases 0.000 claims 20
- 208000002193 Pain Diseases 0.000 claims 17
- 230000002981 neuropathic effect Effects 0.000 claims 14
- 208000000094 Chronic Pain Diseases 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 229960001796 sunitinib Drugs 0.000 claims 4
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 4
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 claims 3
- 229950006304 gilteritinib Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 3
- 229950010895 midostaurin Drugs 0.000 claims 3
- 229950001626 quizartinib Drugs 0.000 claims 3
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000011552 rat model Methods 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- GKEYKDOLBLYGRB-LGMDPLHJSA-N 5-[2-(diethylamino)ethyl]-2-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1h-pyrrolo[3,2-c]pyridin-4-one Chemical compound O=C\1NC2=CC=C(F)C=C2C/1=C/C(N1)=C(C)C2=C1CCN(CCN(CC)CC)C2=O GKEYKDOLBLYGRB-LGMDPLHJSA-N 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- MLIFNJABMANKEU-UHFFFAOYSA-N cep-5214 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCO)C4=C3CC2=C1 MLIFNJABMANKEU-UHFFFAOYSA-N 0.000 claims 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000007933 dermal patch Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940125199 famitinib Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- UHEBDUAFKQHUBV-UHFFFAOYSA-N jspy-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000001032 spinal nerve Anatomy 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000007939 sustained release tablet Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 238000012447 xenograft mouse model Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305669.0 | 2016-06-08 | ||
| EP16305669.0A EP3254698A1 (en) | 2016-06-08 | 2016-06-08 | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| PCT/EP2017/063935 WO2017211937A1 (en) | 2016-06-08 | 2017-06-08 | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517536A JP2019517536A (ja) | 2019-06-24 |
| JP2019517536A5 true JP2019517536A5 (OSRAM) | 2020-05-07 |
| JP7134097B2 JP7134097B2 (ja) | 2022-09-09 |
Family
ID=56134285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563716A Active JP7134097B2 (ja) | 2016-06-08 | 2017-06-08 | 神経障害性疼痛の治療のための低用量ｆｌｔ３受容体阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10709687B2 (OSRAM) |
| EP (2) | EP3254698A1 (OSRAM) |
| JP (1) | JP7134097B2 (OSRAM) |
| HU (1) | HUE062092T2 (OSRAM) |
| WO (1) | WO2017211937A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020212395A1 (en) * | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| KR102231446B1 (ko) * | 2021-01-21 | 2021-03-24 | (주) 와이디생명과학 | 베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물 |
| AU2022426699A1 (en) | 2021-12-30 | 2024-07-11 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2687702A (en) | 2000-10-17 | 2002-04-29 | Merck & Co Inc | Orally active salts with tyrosine kinase activity |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| US7101884B2 (en) | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| DK1441737T3 (da) | 2001-10-30 | 2006-11-13 | Novartis Ag | Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet |
| AU2002360753B2 (en) | 2001-12-27 | 2008-08-21 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| US7304071B2 (en) | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| KR20050037585A (ko) | 2002-08-23 | 2005-04-22 | 카이론 코포레이션 | 벤지미다졸 퀴놀리논 및 그들의 사용 |
| JPWO2004039782A1 (ja) | 2002-10-29 | 2006-03-02 | 麒麟麦酒株式会社 | Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| CA2501932C (en) | 2002-11-13 | 2014-03-11 | Chiron Corporation | Use of benzimidazole quinolinones for treating cancer |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| DE60326646D1 (de) | 2002-12-18 | 2009-04-23 | Vertex Pharma | Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| CN101340909B (zh) | 2005-10-18 | 2012-01-11 | 詹森药业有限公司 | 抑制flt3激酶的方法 |
| PL2001892T3 (pl) | 2006-03-17 | 2013-09-30 | Ambit Biosciences Corp | Imidazolotiazolowe związki do leczenia chorób proliferacyjnych |
| CN101835472A (zh) | 2007-11-08 | 2010-09-15 | 埃姆比特生物科学公司 | N-(5-叔丁基-异噁唑-3-基)-N′-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2,1-b][1,3]苯并噻唑-2-基]苯基}脲治疗增殖性疾病的给药方法 |
| CA2713553A1 (en) | 2008-02-01 | 2009-08-06 | Akinion Pharmaceuticals Ab | Pyrazine derivatives and their use as protein kinase inhibitors |
| EP2521782B1 (en) | 2010-01-05 | 2019-04-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Flt3 receptor antagonists for the treatment or the prevention of pain disorders |
| AU2015295288B2 (en) * | 2014-07-31 | 2019-10-31 | Centre National De La Recherche Scientifique (Cnrs) | FLT3 receptor antagonists |
-
2016
- 2016-06-08 EP EP16305669.0A patent/EP3254698A1/en not_active Withdrawn
-
2017
- 2017-06-08 EP EP17727913.0A patent/EP3468602B1/en active Active
- 2017-06-08 JP JP2018563716A patent/JP7134097B2/ja active Active
- 2017-06-08 HU HUE17727913A patent/HUE062092T2/hu unknown
- 2017-06-08 US US16/307,968 patent/US10709687B2/en active Active
- 2017-06-08 WO PCT/EP2017/063935 patent/WO2017211937A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536176A5 (OSRAM) | ||
| JP2009536147A5 (OSRAM) | ||
| JP2019517536A5 (OSRAM) | ||
| JP2016540021A5 (OSRAM) | ||
| JP2008520736A5 (OSRAM) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| JP2016147915A5 (OSRAM) | ||
| ATE543489T1 (de) | Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür | |
| JP2019517542A5 (OSRAM) | ||
| JP2017506624A5 (OSRAM) | ||
| JP2015528471A5 (OSRAM) | ||
| JP2016185995A5 (OSRAM) | ||
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| JP2018507243A5 (OSRAM) | ||
| RU2013106172A (ru) | Композиция для снятия усталости, состав и их применение | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| ME02474B (me) | Terapijski režimi | |
| JP2014507475A5 (OSRAM) | ||
| JP2018039810A5 (OSRAM) | ||
| JP2011516544A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| JP2019507786A5 (OSRAM) | ||
| HRP20251123T1 (hr) | Ekopipam za liječenje touretteovog sindroma | |
| JP2014503589A5 (OSRAM) | ||
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol |